Want to see IN:BLISSGVS full AI Analyst Report?
BLISSGVS Stock Chart & Stats
₹144.75
-₹6.85(-3.92%)
At close: 4:00 PM EST
₹144.75
-₹6.85(-3.92%)
Day’s Range― - ―
52-Week Range₹118.35 - ₹733.75
Previous CloseN/A
Volume571.01K
Average Volume (3M)21.48K
Market Cap
₹72.31B
Enterprise Value₹21.82K
Total Cash (Recent Filing)₹1.89B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)53.4
Beta1.14
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.22%
Share Statistics
EPS (TTM)12.78
Shares Outstanding106,275,220
10 Day Avg. Volume20,695
30 Day Avg. Volume21,484
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)2.03
Price to Sales (P/S)2.61
P/FCF Ratio29.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue And EPS GrowthRevenue growth of 20.6% and EPS growth of 27.2% indicate expanding sales and earnings capacity. If sustained, this combination can support greater scale, reinforce market presence, and provide resources for product and geographic development.
Conservative Balance SheetLow and declining debt alongside rising assets and equity provides financial resilience and flexibility. A conservative capital structure can support continued investment in pharmaceutical products and markets while reducing pressure on cash flows during weaker periods.
Improving Cash GenerationStrong recent operating and free cash flow improves the company’s ability to fund operations, investment, and growth internally. The sharp free-cash-flow rebound also strengthens liquidity and reduces reliance on external financing for ongoing business needs.
Bears Say
Earnings VolatilityHistorical margin volatility and the pronounced 2022 profit weakness indicate that earnings power has not been consistently stable. Such fluctuations can make future profitability harder to forecast and may limit confidence in the durability of reported growth.
Choppy Cash ConversionUneven cash conversion, including a prior year of negative free cash flow, means accounting earnings may not consistently translate into available cash. This variability can complicate investment planning and make internally funded expansion less predictable.
Operating Profitability ClarityLimited margin detail and an unusual relationship between EBITDA and EBIT reduce clarity around the quality and sustainability of operating profits. Greater uncertainty in underlying profitability makes it harder to assess how efficiently growth is being converted into earnings.
Bliss Gvs Pharma Limited News
BLISSGVS FAQ
What was Bliss Gvs Pharma Limited’s price range in the past 12 months?
Bliss Gvs Pharma Limited lowest stock price was ₹118.35 and its highest was ₹733.75 in the past 12 months.
What is Bliss Gvs Pharma Limited’s market cap?
Bliss Gvs Pharma Limited’s market cap is ₹72.31B.
When is Bliss Gvs Pharma Limited’s upcoming earnings report date?
Bliss Gvs Pharma Limited’s upcoming earnings report date is Oct 23, 2026 which is in 32 days.
How were Bliss Gvs Pharma Limited’s earnings last quarter?
Bliss Gvs Pharma Limited released its earnings results on Aug 12, 2026. The company reported ₹4.73 earnings per share for the quarter.
Is Bliss Gvs Pharma Limited overvalued?
According to Wall Street analysts Bliss Gvs Pharma Limited’s price is currently Overvalued.
Does Bliss Gvs Pharma Limited pay dividends?
Bliss Gvs Pharma Limited pays a Semiannually dividend of ₹1 which represents an annual dividend yield of 0.22%. See more information on Bliss Gvs Pharma Limited dividends here
What is Bliss Gvs Pharma Limited’s EPS estimate?
Bliss Gvs Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bliss Gvs Pharma Limited have?
Bliss Gvs Pharma Limited has 106,275,220 shares outstanding.
What happened to Bliss Gvs Pharma Limited’s price movement after its last earnings report?
Bliss Gvs Pharma Limited reported an EPS of ₹4.73 in its last earnings report. Following the earnings report the stock price went down -1.463%.
Which hedge fund is a major shareholder of Bliss Gvs Pharma Limited?
Currently, no hedge funds are holding shares in IN:BLISSGVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bliss Gvs Pharma Limited
Established in 1984 and headquartered in Mumbai, India, Bliss GVS Pharma Limited specializes in the development, manufacturing, and distribution of a comprehensive array of pharmaceutical products. The company's pharmaceutical portfolio includes an extensive range of dosage forms, such as oral solids (tablets, capsules), various liquid and injectable preparations, topical applications (creams, gels), and advanced drug delivery systems like transdermal patches. Beyond conventional medicines, Bliss GVS also offers a diverse selection of other healthcare and personal care items, including balms, lotions, shampoos, and over-the-counter remedies. Their therapeutic focus is equally broad, encompassing solutions for anti-infectives, pain management, gastrointestinal issues, anti-malarials, dermatological conditions, nutritional support, and a wide variety of other wellness and hygiene products, including medicated and cosmetic soaps. The company actively engages in international exports, extending its market presence beyond India.
Technical Analysis
Innova Captab Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Orchid Pharma Limited
―
RPG Life Sciences Limited
―
Unichem Laboratories Limited
―